Here I’ll do you one better. “The Plains of

New Post Public Reply Private Reply Replies (1) Message Board
Riztheinvestor sean007 #135574
803

Here I’ll do you one better.

“The Plains of Hesitation.

I've been thinking about all of my investments over the last three decades and most recently within the last two decades, my experience with investing in the biotech space. Because of this experience, I want to share with new or young investors what I've found to be the good, the bad and the ugly about biotech investing. I can't possibly cover everything but, want to touch on just a few. Some will call it conspiracies but, it's not a conspiracy if it's true and I have plenty of examples, not anecdotal fluff.

First, my reasons why? Thirty years ago, the technology to share information, as we know it today did not exist. The Internet was just coming out of its infancy into the market. It had always been part of the US Defense technology, spearheaded by the Defense Advanced Research Projects Agency (DARPA), but was not available to the masses. I still remember the commentary in the news that this couldn't work, for many reasons but at the time because home computing had just got off the ground in the 1980s and dial up modems were the only connection, combined with bytes at low levels and processors being first iterations, i.e.; "The Intel" 16 bit processors. I was happy getting my first Hewlett Packard that ran on 64 bits, and upgraded to 128 bits when I purchased it from Circuit City. It was the shizzle! Apple phones weren't what you carried, rather flip phones, Blackberry phones or satellite phones. My pager was more valuable to me at the time than my computer. So, wrapping this paragraph up, nobody could share their experience with you unless you read the ticker in the paper the next day, heard from a friend or took advice from your broker.

Now, the meat and potatoes.
The Bad! In my personal humble opinion, the bad is lead by the bureaucracy at the FDA. Honestly, they have put such a bad taste in my mouth after watching what they do to small research and development companies with "unproven" promising technology. The wheels turn at turtle speed, they give advice on clinical trial design that is either unwarranted, later disregarded or rejected by the next level of FDA oversight as not being rigorous enough, lacks population size i.e.; (demographics), moved the goal posts, now want more than ABC and want ABCDEFG, out of the blue ask for comparisons to biomarker groups to determine if improved outcomes can be demonstrated, etc. You get the picture. Worst of all, it can happen at any phase of trials along what is already a 10-13 year journey for drug approval! Over the course of time, the share price rises on approvals and can drop on news of more FDA delays. Yes, they serve a purpose and I'm not saying they are at fault. Just bringing it out into the light for new biotech investors what typically awaits them. The longer the research takes, the more delays are likely to occur thus, the lower the SP can go.

The second "bad", if you can imagine this is Wall Street. Can't say I have firsthand relationships with the ilks of people such as Martin Shkreli, but we have plenty of examples of bad actors who for one reason or the other have taken overt actions to destroy biotechs. Martin Shkreli, you may know him as "Pharma Bro" but, before his involvement with buying a pharma and raising prices, he ran his own hedge fund. He personally would write a persuasive argument against a drugs approval and send the letters to the FDA ADCOM committee hearings before voting on whether to move forward with a drugs approval. He would hold a large short position in a company and for dubious reasons, execute a plan to destroy the wealth of shareholders, catch and kill new technology and smile at you with that smug face while hiding behind his veil of lies and deceit. He finally was convicted and sent to prison, although out now, for his lack of moral character and deceit.

If the cards aren't already stacked against you in this space with two "bad" concerns, I'll add a third. There are behemoth large cap pharmaceutical players ($200B+) who spend billions of dollars to buy small companies in order to further their science, whether infectious diseases, medical devices, oncology, transplants, and the various sub-research categories such as stem cell, CAR-T, mRNA/DNA, mAbs, etc and on marketing and sales in order to drive out competition, keep market share and prevent the paradigm shifting new drug/technology from either cannibalizing their products and to dampen any threat they perceive as creative destruction. They're directly in competition with each other and small cap biotech research companies are collateral damage in the crossfire.

The Ugly! Research and Development companies are not typically flush with cash. In fact, frequent fund raising is a huge part the CEOs goals. They travel all over the United States and will get 10-15 minutes to do a presentation in order to expose institutional investors to the XYZ "story" that is their brand, pipeline, discoveries, current assets, and people of XYZ Biotech. Not so bad, right? Whether through dilution, credit facilities, issuance of convertible debt/bond instruments and the like, these efforts while necessary, can adversely impact your investment. A lot of the time spent at these healthcare conferences for early stage biotech's is spent on finding a source, book maker, a financial institution that specializes in providing finance options to the CEO, who will later transact a share offering ( or some other instrument) and in return, the book makers profit from the deal. It's a never ending death by a thousand cuts of toxic financing that typically damages the share price.

So, several examples that create wealth destruction for biotech investors; Delays by the FDA, WS greed, large cap pharmaceuticals preserving their stranglehold on the market and toxic finance deals. Can there be any good left? What have I learned that leads me to the good? Well, to start, I try to navigate and circumvent around, over and under all of the bad. First, I never buy for the long term into a biotech that is just starting out. The novelty of their ideas generates a large swell of interest at the beginning. Once the honeymoon affect wears off, the slow walk down into the death spiral begins. While that sounds bad, it is usually for these who bought into the hype at the beginning. While WS is profiting off deals, running up SP and creating FOMO, they drag it back down. Buyers lose interest, algorithms takeover and before you know it, you are trading on the OTC in decimals out to one thousand.

But, what if you found a company that has been in existence for decade(s), suffered through all of the bad (outlined above) either through self-affliction, poor corporate oversight, poor fiscal management, unsound accounting principles, FDA delays, sabotage, etc. yet they owned a drug that is well established in the medical community, the drug's safety profile was well-known and supported with volumes of publications, clinical trials were well underway and results showed promise and most, if not all of the suffering over a decade that happened to early investors was years and years out of your way? As a bonus, the ridiculous "once in a life time" share price is still at rock bottom prices? Relatively speaking, this has been in the ball park below one dollar since January 2022 with the exception of a brief 5 day run up in late July-early August 2022.

Do you scoff at the opportunity, still concerned with the "Bad and the Ugly," when I detailed for you who, what, when, why and how transformative biotechs with promising technology find themselves in such a demise? If you just discovered CYDY, you are one lucky investor. Their drug, Leronlimab is a blockbuster drug with such attention by those I've described above. I implore you to do the research on every thing I've said. Join chat groups, GOOGLE "Leronlimab" and "CCR5" and learn the method of action of this drug and, read why HIV positive patients such as Charlie Sheen have publicly stated this drug aka PRO140 saved their lives. If you read all of this and find yourself asking "Do I go ahead and toss some money here or do I wait", I share with you this favorite quote of mine, "Upon the plains of hesitation bleached the bones of countless millions who sat down to wait..and while waiting, they died. (Anonymous)

Pardon any grammatical or spelling errors. Give the old guy a break!

​”

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces Class Action: Investors Beware

Updated Category News Views 0

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

Continue Reading
Morpho Unveils Versatile UV Printer at IFA 2026

Updated Category News Views 4

IFA 2026: A New Frontier for Desktop Printing You've seen your fair share of printers over the years, but when a company like Morpho steps onto the scene with a gadget that echoes innovation, it makes you perk up those market-ears. We're talking the big unveil of their desktop UV printer at the IFA 2026 in Berlin. Morpho's contraption isn't just spewing out ink; it's...

Continue Reading
Softcare Facilitates Standards Delegation Visit to Senegal

Updated Category News Views 2

Ever seen a whole nation's hygiene industry getting a deep dive from not just one, but three major standards bodies? That's what just went down in Senegal. Softcare opened its doors wide to folks from the Senegalese Association for Standardization (ASN), the International Organization for Standardization (ISO), and the Swedish Institute for Standards (SIS). This was no...

Continue Reading
Midea's VitaBreeze: Revolutionizing Personalized Climate

Updated Category News Views 0

A Fresh Breeze in Climate Control Here's something that'll shake up your household. Midea just announced their latest gizmo, called VitaBreeze, and they’re not messing around. They introduced it at IFA 2026, promising it's not just for cooling off in the summer or heating in the winter. Oh no, my friends, they've packed this unit with enough cutting-edge tech that...

Continue Reading
Why Buyers Are Flocking to Whidbey Island Homes

Updated Category News Views 2

Something's got folks eyeing Whidbey Island like a gambler with a hot tip—and it ain't just the thrill of a vacation spot. Anyone with half a brain knows real estate moves in waves, and right now, Whidbey Island's caught some serious momentum. You can't ignore the pull of natural beauty, access to city life, and that laid-back vibe that seems to whisper "slow down and...

Continue Reading
DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

Updated Category News Views 0

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 4

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 0

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Changhong's IFA 2026 Showcase: AI, Culture & Localization

Updated Category News Views 2

Changhong's Game Plan: From Global Reach to Local Touch Well, Changhong's not sitting back at IFA 2026, let me tell you that. This isn't your run-of-the-mill showcase; it's a full-on reveal of what happens when a company takes AI tech and tunes it to the heartbeat of daily life. TVs, fridges, air conditioners—you name it, they've got an AI twist on it. But is this just...

Continue Reading
Ice-Rock Avalanches: Future Risks and Urgent Lessons

Updated Category News Views 1

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the P/E Ratio of Amazon.com Inc. for Investors

Updated Category News Views 216

Analyzing the P/E Ratio of Amazon.com Inc. As of now, Amazon.com Inc. (NASDAQ: AMZN) is showing a stock price of $222.42, marking a notable increase of 2.74%. This uptick over the recent month reflects a gain of 0.78%, while over the past year, the stock has appreciated by an impressive 20.42%. For long-term shareholders, this upward trend is a positive signal. However,...

Continue Reading
DIRTT Environmental Solutions Plans Renewal of NCIB for Debentures

Updated Category News Views 96

DIRTT Environmental Solutions Announces Renewal of NCIB DIRTT Environmental Solutions Ltd. (TSX: DRT; OTC: DRTTF) has made headlines with its strategic decision to renew its normal course issuer bid (NCIB) for specific convertible unsecured subordinated debentures. This anticipated renewal indicates the company’s proactive approach in managing its financial assets and...

Continue Reading
Celebrating Legal Excellence: Ervin Cohen & Jessup Partners Shine

Updated Category News Views 141

Partners at Ervin Cohen & Jessup Honored as Legal Visionaries In a recent announcement, Ervin Cohen & Jessup LLP has proudly recognized two of its esteemed partners for their exceptional contributions to the legal field. Partners Kelly Cunningham and Chris Manderson have been honored by a prominent publication as "Legal Visionaries," showcasing their expertise and...

Continue Reading
EXL's Innovative LDS Platform Shines as a Luminary in 2025

Updated Category News Views 284

EXL Recognized for Excellence in Life Insurance Technology EXL [NASDAQ: EXLS], a leader in data and artificial intelligence, has received an esteemed designation as a "Luminary" in a significant report focusing on new business and underwriting systems for life insurance in North America. This recognition, awarded by Celent, underscores EXL's commitment to innovation in...

Continue Reading
Greenbacker Renewable Energy's Earnings Show Resilience

Updated Category News Views 264

Greenbacker Contributions to Sustainable Energy Greenbacker Renewable Energy Company, LLC, continues to forge ahead in the renewable energy sector, demonstrating a strong commitment to sustainability and profitability. The company effectively advanced its mission by executing strategic non-core asset sales, which have positioned it for further financial growth and...

Continue Reading